 Ticlopidine
"Ticlopidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Ticlopidine is an effective inhibitor of platelet aggregation. The drug has been found to significantly reduce infarction size in acute myocardial infarcts and is an effective antithrombotic agent in arteriovenous fistulas, aorto-coronary bypass grafts, ischemic heart disease, venous thrombosis, and arteriosclerosis.
| Descriptor ID |
D013988
|
| MeSH Number(s) |
D02.886.778.823.500 D03.383.725.849.500 D03.383.903.830.500 D03.438.928.500
|
| Concept/Terms |
Ticlodix- Ticlodix
- Vitoria Brand of Ticlopidine Hydrochloride
Ticlodone- Ticlodone
- Almirall Brand of Ticlopidine Hydrochloride
Ticlid- Ticlid
- Roche Brand of Ticlopidine Hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Ticlopidine".
Below are MeSH descriptors whose meaning is more specific than "Ticlopidine".
This graph shows the total number of publications written about "Ticlopidine" by people in UAMS Profiles by year, and whether "Ticlopidine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 2 | 0 | 2 | | 2015 | 3 | 1 | 4 | | 2014 | 2 | 0 | 2 | | 2013 | 2 | 1 | 3 | | 2012 | 2 | 2 | 4 | | 2010 | 1 | 0 | 1 | | 2009 | 2 | 1 | 3 | | 2006 | 1 | 0 | 1 | | 2005 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Ticlopidine" by people in Profiles over the past ten years.
-
Nairooz R, Valgimigli M, Rochlani Y, Pothineni NV, Raina S, Sardar P, Mukherjee D, Naidu SS, Shavelle DM. Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy. Int J Cardiol. 2017 Feb 15; 229:82-89.
-
Meena N, Abouzgheib W, Patolia S, Rosenheck J, Boujaoude Z, Bartter T. EBUS-TBNA and EUS-FNA: Risk Assessment for Patients Receiving Clopidogrel. J Bronchology Interv Pulmonol. 2016 Oct; 23(4):303-307.
-
Jain N, Li X, Adams-Huet B, Sarode R, Toto RD, Banerjee S, Hedayati SS. Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease. Am J Cardiol. 2016 Feb 15; 117(4):656-663.
-
Hoh BL, Gong Y, McDonough CW, Waters MF, Royster AJ, Sheehan TO, Burkley B, Langaee TY, Mocco J, Zuckerman SL, Mummareddy N, Stephens ML, Ingram C, Shaffer CM, Denny JC, Brilliant MH, Kitchner TE, Linneman JG, Roden DM, Johnson JA. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease. J Neurosurg. 2016 Jun; 124(6):1746-51.
-
Nairooz R, Ayoub K, Shavelle D. Duration of Triple Therapy: A Clinical Question Yet to Be Answered. J Am Coll Cardiol. 2015 Nov 17; 66(20):2266.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|